Mercier Joel, Provins Laurent, Valade Anne
UCB Pharma, Braine l'Alleud, Belgium.
UCB Pharma, Braine l'Alleud, Belgium.
Drug Discov Today Technol. 2017 Nov;25:45-52. doi: 10.1016/j.ddtec.2017.11.003. Epub 2017 Dec 1.
Imaging synaptic density in vivo has promise for numerous research and clinical applications in the diagnosis and treatment monitoring of neurodegenerative and psychiatric diseases. Recent developments in the field of PET, such as SV2A human imaging with the novel tracers UCB-A, UCB-H and UCB-J, may help in realizing this potential and bring significant benefit for the patients suffering from these diseases. This review provides an overview of the most recent progress in the field of SV2A PET imaging, its potential for use as a biomarker of synaptic density and the future development areas.
在体内成像突触密度在神经退行性疾病和精神疾病的诊断及治疗监测的众多研究和临床应用中具有前景。正电子发射断层扫描(PET)领域的最新进展,例如使用新型示踪剂UCB - A、UCB - H和UCB - J进行突触囊泡蛋白2A(SV2A)人体成像,可能有助于实现这一潜力,并为患有这些疾病的患者带来显著益处。本综述概述了SV2A PET成像领域的最新进展、其作为突触密度生物标志物的应用潜力以及未来的发展领域。